{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:09:35Z","timestamp":1789546175762,"version":"build-2803163510"},"reference-count":59,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T00:00:00Z","timestamp":1760227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"Cancer Society","doi-asserted-by":"crossref","award":["23 2645 PjF 01H"],"award-info":[{"award-number":["23 2645 PjF 01H"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Swedish Cancer Society","award":["24 3523 Pj"],"award-info":[{"award-number":["24 3523 Pj"]}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2023-02158"],"award-info":[{"award-number":["2023-02158"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","award":["2022-00556"],"award-info":[{"award-number":["2022-00556"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Prostatacancerfonden","award":["PK"],"award-info":[{"award-number":["PK"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: The gastrin-releasing peptide receptor (GRPR) shows high-density expression in prostate cancer (PCa), especially in the early stages of the disease. The introduction of a safe radiotracer for assessing GRPR-expression in PCa may serve as an alternative or complementary tracer to PSMA-directed probes for patients with insufficient PSMA expression. In the present study, the tolerability and safety, biodistribution, and dosimetry of the new GRPR-targeting radiopeptide [99mTc]Tc-DB8 were investigated for the first time in male PCa patients. A mass escalation study was performed, aiming to improve tumor-to-background contrast and, thereby, to enhance diagnostic accuracy. Methods: Sixteen male patients were enrolled in a single-center diagnostic open-label exploratory Phase I clinical trial. Patients were administered a single intravenous injection of 40, 80, or 120 \u00b5g of [99mTc]Tc-DB8 peptide (n = 5\u20136) and underwent whole-body planar imaging (anterior and posterior) 2, 4, 6, and 24 h post-injection (pi) and SPECT-CT acquisition 2, 4, and 6 h pi. Results: Administration of [99mTc]Tc-DB8 was well tolerated at all tested peptide masses. The effective dose did not differ significantly between the injected peptide mass and was 0.005 \u00b1 0.003 mSv\/MBq. High activity uptake was observed in the pancreas and kidneys, which 3-fold decreased with an increasing injected peptide mass from 40 to 120 \u00b5g. The activity uptake in primary tumors did not differ significantly between cohorts injected with different peptide masses [SUVmax 1.65\u20139.96]. The tumor-to-muscle ratios increased with time and were the highest for the cohort injected with 120 \u00b5g of peptide, 7.2 \u00b1 3.1 (4.64-11-25) at 4 h pi. Conclusions: Single intravenous administration of [99mTc]Tc-DB8, for visualization of GRPR expression in PCa using SPECT imaging was well tolerated in a peptide mass range of 40\u2013120 \u00b5g. An injected peptide mass of 80\u2013120 \u00b5g\/patient and SPECT acquisition 2\u20134 h pi were found to be optimal for further clinical studies due to the significantly lower activity accumulation in the pancreas and kidneys.<\/jats:p>","DOI":"10.3390\/pharmaceutics17101323","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T08:10:31Z","timestamp":1760343031000},"page":"1323","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase I Clinical Study with the GRPR-Antagonist [99mTc]Tc-DB8 for SPECT Imaging of Prostate Cancer: Does the Injected Peptide Mass Make a Difference?"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6120-2683","authenticated-orcid":false,"given":"Anna","family":"Orlova","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden"},{"name":"Science for Life Laboratory, Uppsala University, 752 37 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Rybina","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia"},{"name":"Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Medvedeva","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia"},{"name":"Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Zelchan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia"},{"name":"Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Bragina","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia"},{"name":"Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2061-8417","authenticated-orcid":false,"given":"Liubov","family":"Tashireva","sequence":"additional","affiliation":[{"name":"Department of General and Molecular Pathology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia"},{"name":"The Laboratory of Molecular Therapy of Cancer, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634028 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1176-2441","authenticated-orcid":false,"given":"Maria","family":"Larkina","sequence":"additional","affiliation":[{"name":"Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia"},{"name":"Department of Pharmaceutical Analysis, Siberian State Medical University, 634050 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4282-3198","authenticated-orcid":false,"given":"Ruslan","family":"Varvashenya","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia"},{"name":"Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia"},{"name":"Department of Pharmaceutical Analysis, Siberian State Medical University, 634050 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadejda","family":"Lushnikova","sequence":"additional","affiliation":[{"name":"Department of General Oncology, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0617-3936","authenticated-orcid":false,"given":"Panagiotis","family":"Kanellopoulos","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Uppsala University, 751 23 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1123-2486","authenticated-orcid":false,"given":"Theodosia","family":"Maina","sequence":"additional","affiliation":[{"name":"Molecular Radiopharmacy, INRaSTES, NCSR \u201cDemokritos\u201d, 15341 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6028-9112","authenticated-orcid":false,"given":"Berthold A.","family":"Nock","sequence":"additional","affiliation":[{"name":"Molecular Radiopharmacy, INRaSTES, NCSR \u201cDemokritos\u201d, 15341 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6122-1734","authenticated-orcid":false,"given":"Vladimir","family":"Tolmachev","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Uppsala University, 752 37 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Chernov","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, 634009 Tomsk, Russia"},{"name":"Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e077738","DOI":"10.1136\/bmj-2023-077738","article-title":"Prostate cancer incidence and mortality in Europe and implications for screening activities: Population based study","volume":"386","author":"Vaccarella","year":"2024","journal-title":"BMJ"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s12149-013-0731-7","article-title":"Choline PET\/CT for imaging prostate cancer: An update","volume":"27","author":"Kitajima","year":"2013","journal-title":"Ann. Nucl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41391-018-0060-y","article-title":"Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer","volume":"21","author":"Miller","year":"2018","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e473636","DOI":"10.1200\/EDBK-25-473636","article-title":"State of the Art: Personalizing treatment for patients with metastatic castration-resistant prostate cancer","volume":"45","author":"Abida","year":"2025","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.7150\/thno.92612","article-title":"PSMA-targeted radiotheranostics in modern nuclear medicine: Then, now, and what of the future?","volume":"14","author":"Sallam","year":"2024","journal-title":"Theranostics"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Sallam, M., Mohammadi, M., Sainsbury, F., Nguyen, N.T., Kimizuka, N., Muyldermans, S., and Benesova-Sch\u00e4fer, M. (2024). Bibliometric and scientometric analysis of PSMA-targeted radiotheranostics: Knowledge mapping and global standing. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1397790"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijrobp.2024.08.045","article-title":"Evolving Paradigms in Prostate Cancer: The Integral Role of Prostate-Specific Membrane Antigen Positron Emission Tomography\/Computed Tomography in Primary Staging and Therapeutic Decision-Making","volume":"121","author":"Udovicich","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2967\/jnumed.115.168393","article-title":"Pilot comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer","volume":"57","author":"Minamimoto","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2967\/jnumed.123.267017","article-title":"Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET\/MRI in Patients with Biochemically Recurrent Prostate Cancer","volume":"65","author":"Duan","year":"2024","journal-title":"J. Nucl. Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Wang, H., Li, G., Zhao, J., Eiber, M., and Tian, R. (2023). Current status of PSMA-targeted imaging and therapy. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1230251"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1517\/14728222.2016.1164694","article-title":"Bombesin related peptides\/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment","volume":"20","author":"Moreno","year":"2016","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_13","first-page":"1152","article-title":"Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation","volume":"59","author":"Markwalder","year":"1999","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/pros.22743","article-title":"Early over-expression of GRP receptors in prostatic carcinogenesis","volume":"74","author":"Waser","year":"2014","journal-title":"Prostate"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/annonc\/mdm058","article-title":"Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy","volume":"18","author":"Cornelio","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Bouchareb, Y., AlSaadi, A., Zabah, J., Jain, A., Al-Jabri, A., Phiri, P., Shi, J.Q., Delanerolle, G., and Sirasanagandla, S.R. (2024). Technological advances in SPECT and SPECT\/CT imaging. Diagnostics, 14.","DOI":"10.3390\/diagnostics14131431"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Verhoeven, M., Ruigrok, E.A.M., van Leenders, G.J.H.H., van den Brink, L., Balcioglu, H.E., van Weerden, W.M., and Dalm, S.U. (2023). GRPR versus PSMA: Expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1199432"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Mansi, R., Nock, B.A., Dalm, S.U., Busstra, M.B., van Weerden, W.M., and Maina, T. (2021). Radiolabeled bombesin analogs. Cancers, 13.","DOI":"10.3390\/cancers13225766"},{"key":"ref_19","first-page":"S221","article-title":"Lu-177-AMBA Bombesin Analogue in Hormone Refractory Prostate Cancer Patients: A Phase I Escalation Study with Single-Cycle Administrations","volume":"34","author":"Bodei","year":"2007","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_20","first-page":"45","article-title":"Action of bombesin on human gastrointestinal motility","volume":"6","author":"Bertacinni","year":"1974","journal-title":"Ital. J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/1040-8428(96)00220-X","article-title":"Bombesin receptor antagonists","volume":"24","author":"Gozzini","year":"1996","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.116.178889","article-title":"Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: Preclinical and first clinical results","volume":"58","author":"Nock","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1021\/acs.jmedchem.8b00177","article-title":"New gastrin releasing peptide receptor-directed [99mTc]Demobesin 1 mimics: Synthesis and comparative evaluation","volume":"61","author":"Nock","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0020-708X(85)90093-6","article-title":"Chemical and Biological Properties of a Cationic Tc-Tetraamine Complex","volume":"36","author":"Pfeiffer","year":"1985","journal-title":"Int. J. Appl. Radiat. Isot."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s11307-014-0754-z","article-title":"GRP receptor imaging of prostate cancer using [99mTc]Demobesin 4: A first-in-man study","volume":"16","author":"Mather","year":"2014","journal-title":"Mol. Imaging Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1007\/s002590000355","article-title":"Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: A feasibility study","volume":"27","author":"Dumont","year":"2000","journal-title":"Eur. J. Nucl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1021\/ic9706562","article-title":"Rhenium(V) and Technetium(V) Oxo complexes of an N2N\u2019S peptidic chelator: Evidence of interconversion between the Syn and Anti conformations","volume":"36","author":"Wong","year":"1997","journal-title":"Inorg. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Chernov, V., Rybina, A., Zelchan, R., Medvedeva, A., Bragina, O., Lushnikova, N., Doroshenko, A., Usynin, E., Tashireva, L., and Vtorushin, S. (2023). Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors. Cancers, 15.","DOI":"10.3390\/cancers15061631"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Nock, B.A., Kaloudi, A., Kanellopoulos, P., Janota, B., Bromi\u0144ska, B., I\u017cycki, D., Miko\u0142ajczak, R., Czepczynski, R., and Maina, T. (2021). [99mTc]Tc-DB15 in GRPR-targeted tumor imaging with SPECT: From preclinical evaluation to the first clinical outcomes. Cancers, 13.","DOI":"10.3390\/cancers13205093"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13550-024-01105-6","article-title":"Biodistribution and radiation dosimetry of [99mTc]Tc-N4-BTG in patients with biochemical recurrence of prostate cancer","volume":"14","author":"Rinscheid","year":"2024","journal-title":"EJNMMI Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Bragina, O., Chernov, V., Larkina, M., Varvashenya, R., Zelchan, R., Medvedeva, A., Ivanova, A., Tashireva, L., Maina, T., and Nock, B.A. (2025). The impact of the injected mass of the gastrin-releasing peptide receptor antagonist on uptake in breast cancer: Lessons from a Phase I trial of [99mTc]Tc-DB8. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17081000"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1021\/acsptsci.4c00637","article-title":"Single-Photon Emission Computer Tomography Imaging of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Cancer Patients Using a Novel Peptide-Based Probe [99mTc]Tc-BQ0413 with Picomolar Affinity to PSMA: A Phase I\/II Clinical Study","volume":"8","author":"Medvedeva","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.2967\/jnumed.116.188011","article-title":"Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors","volume":"58","author":"Morgat","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1006\/frne.2001.0217","article-title":"Hypothalamic hormones and cancer","volume":"22","author":"Schally","year":"2001","journal-title":"Front. Neuroendocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10637-006-6886-5","article-title":"A phase I trial of the bombesin\/gastrin-releasing peptide (BN\/GRP) antagonist RC3095 in patients with advanced solid malignancies","volume":"24","author":"Schwartsmann","year":"2006","journal-title":"Investig. New Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"12052","DOI":"10.1016\/S0021-9258(19)38506-0","article-title":"Chronic desensitization to bombesin by progressive down-regulation of bombesin receptors in Swiss 3T3 cells. Distinction from acute desensitization","volume":"265","author":"Millar","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2967\/jnumed.107.045054","article-title":"Bombesin receptor antagonists may be preferable to agonists for tumor targeting","volume":"49","author":"Cescato","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","article-title":"68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: A systematic review and meta-analysis","volume":"4","author":"Picchio","year":"2018","journal-title":"Eur. Urol. Focus"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1053\/j.semnuclmed.2025.01.001","article-title":"Diagnostic Value of Gastrin-Releasing Peptide Receptor-Targeted PET Imaging in Oncology: A Systematic Review","volume":"55","author":"Mohseninia","year":"2025","journal-title":"Semin. Nucl. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.7150\/thno.14958","article-title":"Gastrin-releasing peptide receptor imaging in breast cancer using the receptor antagonist 68Ga-RM2 And PET","volume":"6","author":"Stoykow","year":"2016","journal-title":"Theranostics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00259-019-04503-4","article-title":"Physiological 68Ga-RM2 uptake in patients with biochemically recurrent prostate cancer: An atlas of semi-quantitative measurements","volume":"47","author":"Baratto","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/en.2002-220371","article-title":"Islet Function Phenotype in Gastrin-Releasing Peptide Receptor Gene-Deficient Mice","volume":"143","author":"Persson","year":"2002","journal-title":"Endocrinology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/RLU.0000000000002209","article-title":"68Ga-NOTA-RM26 PET\/CT in the Evaluation of Breast Cancer: A Pilot Prospective Study","volume":"43","author":"Zang","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2967\/jnumed.117.198929","article-title":"PET using a GRPR antagonist 68Ga-RM26 in healthy volunteers and prostate cancer patients","volume":"59","author":"Zhang","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2165\/00003088-200948030-00001","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"48","author":"Soldin","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1007\/s00259-016-3415-4","article-title":"The EANM practice guidelines for bone scintigraphy","volume":"43","author":"Strobel","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.nucmedbio.2009.11.008","article-title":"In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours\u2014Impact of peptide mass","volume":"37","author":"Velikyan","year":"2010","journal-title":"Nucl. Med. Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2967\/jnumed.107.049502","article-title":"Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy","volume":"49","author":"Morris","year":"2008","journal-title":"J. Nucl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/jnci\/83.2.97","article-title":"Phase I and Imaging Trial of Indium 111-Labeled Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 in Patients With Squamous Cell Lung Carcinoma","volume":"83","author":"Divgi","year":"1991","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.2010.12","article-title":"Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer","volume":"87","author":"Dijkers","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/labinvest.3780192","article-title":"Bombesin Receptors in Distinct Tissue Compartments of Human Pancreatic Diseases","volume":"80","author":"Fleischmann","year":"2000","journal-title":"Lab. Investig."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1007\/s00259-023-06142-2","article-title":"A prospective comparative study of [68Ga]GaRM26 and [68Ga]Ga--PSMA-617 PET\/CT imaging in suspicious prostate cancer","volume":"50","author":"Gao","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/pros.21434","article-title":"Profiling gastrin-releasing peptide receptor in prostate tissues: Clinical implications and molecular correlates","volume":"72","author":"Beer","year":"2012","journal-title":"Prostate"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/pros.20957","article-title":"Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer","volume":"69","author":"Ananias","year":"2009","journal-title":"Prostate"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.euo.2018.08.011","article-title":"Prospective study of the radiolabelled GRPR antagonist BAY86-7548 for positron emission tomography\/computed tomography imaging of newly diagnosed prostate cancer","volume":"2","author":"Touijer","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-12-3490","article-title":"In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548","volume":"19","author":"Jambor","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.2967\/jnumed.120.258814","article-title":"GRPr antagonist 68Ga-SB3 PET\/CT imaging of primary prostate cancer in therapy-na\u00efve patients","volume":"62","author":"Bakker","year":"2021","journal-title":"J. Nucl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00259-023-06483-y","article-title":"Diagnostic accuracy of fully hybrid [68Ga]Ga-PSMA-11 PET\/MRI and [68Ga]Ga-RM2 PET\/MRI in patients with biochemically recurrent prostate cancer: A prospective single-center phase II clinical trial","volume":"51","author":"Ghezzo","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.120.259630","article-title":"PSMA- and GRPR-Targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer","volume":"62","author":"Baratto","year":"2021","journal-title":"Nucl. Med."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/10\/1323\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:31:19Z","timestamp":1760416279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/10\/1323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,12]]},"references-count":59,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["pharmaceutics17101323"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17101323","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,12]]}}}